NuCana plc Sponsored ADR NCNA 深 沪
等待开盘 02-06 09:30:00 美东时间
2.09
-0.290
-12.18%
华盛通- 最 高2.33
- 今 开2.33
- 成交量 8.21万股
- 最 低 2.07
- 昨 收 2.38
- 总市值 869.83万
- 52周最高 268.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.07
- 委 比 72.75%
- 总股本 416.19万
- 历史最高 160000.00
- 量 比 0.83
- 振 幅 10.92%
- 历史最低 2.07
- 每 手 1
- 风险率 72.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NuCana appoints Theresa Bruce as chief operating officer
NuCana (NCNA) announced on Tuesday the appointment of Theresa Bruce as chief operating officer, effective January 1, 2026. Bruce previously served as chief operating officer at Nexus Oncology and has ...
01-06 22:08
NuCana Appoints Theresa Bruce COO, Effective Jan. 1
NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief
01-06 21:01
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana plc has appointed Theresa Bruce as Chief Operating Officer, effective January 1, 2026. With over 25 years of experience in oncology R&D, Bruce will lead the advancement of NuCana's pipeline, including the Phase 1/2 expansion study of NUC-7738 in melanoma and the further development of NUC-3373. Bruce previously served as Senior Vice President of Clinical Operations at NuCana and brings extensive expertise in clinical development. NuCana fo...
01-06 13:00
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana plc presented clinical data at the 2025 ESMO Immuno-Oncology Congress showing continued activity of NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant metastatic melanoma. Results included two partial responses, seven stable disease cases, and no new safety signals. These findings support the potential benefit of NUC-7738 for patients with advanced melanoma, with further enrollment and clinical advancement planned.
2025-12-10 13:00
NuCana GAAP EPS of £0.00
NuCana press release (NCNA): Q3 GAAP EPS of £0.00. NuCana reported a net loss of £0.3 million for the quarter ended September 30, 2025, which includes other income of £2.7 million, as compared to a ne...
2025-11-14 05:54
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana plc announced positive data for its anti-cancer medicines NUC-7738 and NUC-3373, supporting their potential to improve treatment outcomes. Initial data from the expansion study of NUC-7738 is expected in Q4 2025, with final data in 2026. The company is well-capitalized, with cash runway into 2029. NuCana reported a net loss of £0.3 million for Q3 2025 and £26.9 million for the first nine months, but raised £38.4 million via its ATM program...
2025-11-13 21:01
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana plc announced that China's National Intellectual Property Administration granted a key patent for NUC-7738, a novel anti-cancer agent in Phase 1/2 clinical trials for melanoma. This patent strengthens the company's global intellectual property strategy and supports innovative cancer therapies in China. NUC-7738, which disrupts RNA polyadenylation, is being studied in combination with pembrolizumab.
2025-11-05 13:00
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NuCana presented data at ESMO 2025 showing NUC-7738 enhances PD-1 inhibitors' effectiveness in patient-derived organoids from renal cell carcinoma, increasing tumor cell death. This combination targets tumor microenvironment aspects, offering potential benefits for anti-PD-1 refractory cancers. The study supports NUC-7738's mechanism, safety, and efficacy seen in NuTide:701 clinical results, including tumor reduction and prolonged survival in PD-...
2025-10-18 12:00
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
NUC-3373, a thymidylate synthase inhibitor, combined with pembrolizumab, shows promising efficacy and safety in heavily pre-treated patients with advanced solid tumors. A patient with bladder urothelial carcinoma experienced a 100% reduction in tumor lesion size, while a melanoma patient achieved an 81% reduction in target lesions and remains progression-free at 23 months. Preclinical data support NUC-3373's immunogenic effects, including DAMP re...
2025-10-14 12:00
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gain...
2025-10-08 20:01
